Propionate every day

Initial dose should be based upon previous therapy and asthma severity; consideration should be given to current control of asthma symptoms and risk of future exacerbations:

4 to 11 years:

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 50 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 100 mcg twice a day
Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
88 mcg via oral inhalation twice a day
Maximum dose: 88 mcg twice a day

12 years or older:

Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
Patients new to ICS: Initial dose: 88 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum Dose: 880 mcg twice a day

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 1000 mcg twice a day

Fluticasone propionate INHALATION POWDER (Armonair Respiclick[R]): One oral inhalation twice a day
-Initial dose for patients new to ICS: 55 mcg (low dose) via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose of 113 mcg (medium dose) or 232 mcg (high dose) via oral inhalation twice a day
Maximum Dose: 232 mcg twice a day

Fluticasone furoate INHALATION POWDER Arnuity Ellipta[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation once a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 200 mcg once a day

Comments:
-Higher initial doses may be considered in patients with poor asthma control or those who have previously required higher doses of other ICS.
-Inhaled short-acting beta(2)-agonists should be used for immediate relief if symptoms arise between doses.
-Maximum benefit of ICS may not be achieved for up to 2 weeks or longer; if adequate control is not achieved in 2 weeks, may increase dose without exceeding maximum dose.
-After asthma stability has been achieved, titrate to the lowest effective dose to reduce the possibility of side effects.
-Not indicated for the relief of acute bronchospasm.

Use: For the maintenance treatment of asthma as prophylactic therapy.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist in case of:

  • hypersensitivities (allergies) to clobetasol propionate, to other corticosteroids or to any of the other ingredients
  • burns
  • acne
  • severe flushing of skin on and around your nose (rosacea)
  • spotty red rash around your mouth (perioral dermatitis)
  • itching around your back passage (anus) or genitals - unless your doctor has told you to do so
  • bacterial, viral, fungal or parasitic skin infections such as cold sores, varicella (chicken pox), herpes zoster (shingles), impetigo (type of rash on the face), ringworm, athletes foot, thrush, skin tuberculosis or skin disease caused by syphilis
  • ulcerous wounds (weeping wounds) on your scalp

Important Safety Information for Clobex ® (clobetasol propionate) Lotion, %
Clobex ® (clobetasol propionate) Lotion, %, is not recommended for anyone younger than 18 years of age.

Clobex ® Lotion is indicated to treat steroid-responsive dermatoses. Treatment of steroid responsive dermatoses (eczema, dermatitis) should be limited to 2 weeks. Use only as directed by your physician, and do not apply to your face, underarms, or groin and avoid contact with your eyes and lips.

The total dosage should not exceed 50 g (50 mL or fl oz) per week. You should use Clobex ® Lotion only for the minimum period necessary to achieve desired results. In clinical trials, patients reported burning/stinging, skin dryness, irritation, redness, itching, skin thinning and widening of blood vessels. Because too much Lotion passing through your skin may affect your adrenal glands, do not use more than prescribed and stop using the product if you experience nausea, vomiting, fever or low blood pressure, and call you doctor. If you are pregnant, trying to get pregnant or nursing, speak to your doctor before using Clobex ® Lotion.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit /medwatch , or call 1-800-FDA-1088 (1-800-332-1088).

Propionate every day

propionate every day

Important Safety Information for Clobex ® (clobetasol propionate) Lotion, %
Clobex ® (clobetasol propionate) Lotion, %, is not recommended for anyone younger than 18 years of age.

Clobex ® Lotion is indicated to treat steroid-responsive dermatoses. Treatment of steroid responsive dermatoses (eczema, dermatitis) should be limited to 2 weeks. Use only as directed by your physician, and do not apply to your face, underarms, or groin and avoid contact with your eyes and lips.

The total dosage should not exceed 50 g (50 mL or fl oz) per week. You should use Clobex ® Lotion only for the minimum period necessary to achieve desired results. In clinical trials, patients reported burning/stinging, skin dryness, irritation, redness, itching, skin thinning and widening of blood vessels. Because too much Lotion passing through your skin may affect your adrenal glands, do not use more than prescribed and stop using the product if you experience nausea, vomiting, fever or low blood pressure, and call you doctor. If you are pregnant, trying to get pregnant or nursing, speak to your doctor before using Clobex ® Lotion.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit /medwatch , or call 1-800-FDA-1088 (1-800-332-1088).

Media:

propionate every daypropionate every daypropionate every daypropionate every daypropionate every day

http://buy-steroids.org